IGF-1 LR3 Dosage Chart
Practitioner protocols paired with the safety context this peptide actually deserves — hypoglycemia, cancer mitogenicity, and WADA-banned status.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
IGF-1 LR3 is a synthetic analog of insulin-like growth factor-1 with an extended half-life. It is used in research and bodybuilding contexts but is not FDA-approved and carries some of the most serious risk signals on this site. We are publishing this chart with hardened safety context because IGF-1 LR3 information is widely searched — accurate, cautious framing is better than no framing — but PeptideProbe does not recommend its use, and the disclaimers below should be read in full before drawing any conclusions from the dose ranges.
IGF-1 LR3 at a Glance
| Typical dose (community-cited) | 20–50 mcg/day subQ |
|---|---|
| Cycle length (community-cited) | 4 weeks on, 4 weeks off |
| Route | Subcutaneous, sometimes near target muscle |
| FDA status | Not FDA-approved for any human use. Banned by WADA. |
| Source quality | Community / bodybuilding protocols only — no human RCT dosing. |
| Safety status | HIGH RISK — read full safety section before considering use. |
IGF-1 LR3 Reconstitution Chart
How vial size, bacteriostatic water volume, and insulin-syringe units convert for IGF-1 LR3. Use this to translate a prescribed mcg or mg dose into a syringe measurement.
| Vial size | Bac water | Concentration | Dose → insulin-syringe units (U-100) |
|---|---|---|---|
| 1 mg | 1 mL | 1 mg/mL (100 mcg per 0.1 mL) |
|
IGF-1 LR3 Dosing by Use Case
Commonly cited protocols vary by what IGF-1 LR3 is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.
| Use case | Typical dose | Frequency | Cycle length | Notes |
|---|---|---|---|---|
| Research / community use | 20–50 mcg | Once daily | 4 weeks on, 4 weeks off | All protocols are community-derived. Read the safety banner. |
IGF-1 LR3 carries multiple serious risk signals — hypoglycemia, cancer mitogenicity, and WADA-banned status. We do not recommend its use.
- •Hypoglycemia risk: IGF-1 LR3 has insulin-like activity. Multiple suspected bodybuilding deaths have been associated with insulin- or IGF-mediated hypoglycemia, though formal autopsy data is limited.
- •Cancer mitogenicity: IGF-1 is a known mitogen. Epidemiologic studies link elevated circulating IGF-1 to higher rates of breast, prostate, and colorectal cancer. Pharmacologically elevating IGF-1 over months has not been validated as safe.
- •Banned by the World Anti-Doping Agency (WADA) for competitive athletes.
- •Not FDA-approved for any human use.
- •No human dose-ranging trials exist for IGF-1 LR3 specifically. Community protocols are extrapolations.
- •We do not recommend self-administration of IGF-1 LR3 outside of formal medical supervision with a clear clinical indication.
- •ANY personal history of cancer
- •Strong family history of breast, prostate, or colorectal cancer
- •Diabetes (any type)
- •Pregnancy or breastfeeding
- •Anyone competing in WADA-aligned sport
- •Anyone without continuous medical supervision and access to glucose-monitoring tools
IGF-1 LR3 Dosing FAQ
Because IGF-1 LR3 is widely searched and people will encounter dosing information either way. Pairing the dosing with explicit, evidence-based safety context (hypoglycemia case reports, IGF-1 cancer epidemiology, WADA banning) is more protective than leaving the topic uncovered. Our editorial position is that the risks outlined here are serious enough that most readers should not use this peptide.
No. Recombinant IGF-1 (mecasermin, brand name Increlex) is FDA-approved for severe primary IGF-1 deficiency in children — a specific endocrine indication with continuous medical monitoring. IGF-1 LR3 is a research analog with a longer half-life, sold through research-peptide channels, and not FDA-approved.
Reputable peptide therapy clinics generally do not prescribe IGF-1 LR3 due to the safety profile. Clinics that do should be discussed carefully — ask why this is being recommended over safer alternatives like sermorelin, ipamorelin, or tesamorelin which work upstream of IGF-1 with feedback control intact.
Sources
Related Dosage Charts
Want the full IGF-1 LR3 guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for IGF-1 LR3 therapy.
See IGF-1 LR3 guideMedical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.